GSK Plc
Research GSK Plc (GSK) on Bullrun: valuation model: 17.1% undervalued, market cap USD 105.32B, P/E 16.4, dividend yield 3.6%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGSK
- ExchangeNYSE
- CountryUnited Kingdom
- SectorHealthcare
- IndustryDrug Manufacturers-General
- CurrencyUSD
- Valuation signal17.1% undervalued
- Market capUSD 105.32B
- P/E16.4
- Dividend yield3.6%
- Financial periodQ2 2026
- RevenueGBP 8.41B
- Net incomeGBP 435.00M
- Free cash flowGBP 2.04B
- Gross margin73.1%
Valuation Snapshot
Bullrun's latest valuation model marks GSK Plc as 17.1% undervalued; latest market cap is USD 105.32B; P/E is 16.4; dividend yield is 3.6%.
Peer valuation comparison
Latest P/E is 16.4x versus a Healthcare sector median of 24.46x (32.9% below).
Latest dividend yield is 3.61% versus a Healthcare sector median of 2.11% (71.1% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | GBP 32.67B | GBP 5.72B | GBP 4.76B | 72.4% | 2.78 | GBP 3.15B | GBP 17.72B | GBP 16.38B |
| FY2024 | GBP 31.38B | GBP 2.58B | GBP 3.57B | 71.2% | 1.25 | GBP 3.69B | GBP 16.99B | GBP 13.67B |
| FY2023 | n/a | n/a | n/a | n/a | 2.25 | GBP 2.75B | GBP 18.02B | GBP 13.35B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 105.32B | 16.4 | 3.5% | 1.82 |
| 2025 | 2025-12-31 | USD 98.39B | 13.4 | 3.4% | 1.68 |
| 2024 | 2024-12-31 | USD 69.01B | 21.4 | 4.6% | 1.57 |
| 2023 | 2023-12-29 | USD 75.53B | 10.2 | 3.8% | 1.39 |
| 2022 | 2022-12-30 | USD 71.94B | 4.1 | 4.8% | 1.68 |
| 2021 | 2021-12-31 | USD 88.76B | 14.1 | 5.0% | 2.21 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 1.82 USD, yield 3.6%.
| Year | Dividends/share |
|---|---|
| FY2025 | 1.68 GBP |
| FY2024 | 1.57 GBP |
| FY2023 | 1.39 GBP |
About GSK Plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments.
Related stock research
Other Healthcare stocks
Frequently asked questions
Is GSK Plc overvalued or undervalued?
Bullrun's valuation model currently marks GSK Plc as 17.1% undervalued.
What is GSK Plc's market cap?
GSK Plc's market capitalization is USD 105.32B.
What is GSK Plc's P/E ratio?
GSK Plc's price-to-earnings (P/E) ratio is 16.4.
Does GSK Plc pay a dividend?
GSK Plc has a dividend yield of 3.6%.
What does GSK Plc do?
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer.